Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP: